Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Partner Licenses HAP Service to Japanese Med School

NEW YORK, Dec. 11 (GenomeWeb News) - Genaissance Pharmaceuticals will provide its haplotyping services to the Tokyo Women's Medical University for use in drug-response studies, the company said today.


The deal represents the first in a marketing partnership signed between Genaissance and Tokyo-based Intec Web and Genome Informatics Corporation in February 2002.

"We believe numerous Japanese government agencies and pharmaceutical companies plan to conduct genetic variation research over the next few years. We plan to capitalize on those opportunities," said Munehiro Sueoka, president of Intec, said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.